Drug intelligence / Profile preview

LBAL

Development stage: Phase 3
Lead developer: LG Chem
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

LBAL is a biosimilar of Adalimumab, developed by LG Life Sciences. It is an anti-inflammatory agent primarily investigated for the treatment of active Rheumatoid Arthritis. Adalimumab is a recombinant human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor alpha (TNF-alpha) and blocks its interaction with p55 and p75 cell surface TNF receptors, thereby reducing inflammation.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on LBAL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBAL.

Explore the full profile